Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Nov 24;32(11):621–626. doi: 10.1002/clc.20671

Acute Coronary Syndromes: Selective vs Early Invasive Strategies

William E Boden 1,✉, Vipul Gupta 2
PMCID: PMC6653383  PMID: 19938050

Abstract

Recommendations in the 2007 update of the American College of Cardiology/American Heart Association guidelines for patients with non–ST‐elevation myocardial infarction (NSTEMI) provide considerable latitude regarding treatment choices and care pathways. Nevertheless, as accumulating evidence leads to increased recommendations for early invasive strategies, more patients are likely to receive care that falls short of recommendations. While tailoring pharmacotherapy to optimize the risk/benefit ratio for individual patients remains essential, it becomes increasingly important that care paradigms be prospectively defined. To facilitate this goal, we examined key differences between the 2002 and 2007 guidelines and explored data underlying changed recommendations for periprocedural pharmacotherapy. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (125.0 KB).

References

  • 1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non‐ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non‐ST‐Elevation Myocardial Infarction). J Am Coll Cardiol 2007; 50: e1–e157. [DOI] [PubMed] [Google Scholar]
  • 2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non‐ST‐segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) J Am Coll Cardiol 2002; 40: 1366–1374. Available at: http://www.americanheart.org/ downloadable/ heart/1022188973899unstable_may8.pdf. Accessed February 20, 2009. [DOI] [PubMed] [Google Scholar]
  • 3. Brosius FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006; 114: 1083–1087. [DOI] [PubMed] [Google Scholar]
  • 4. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta‐analysis of randomized trials. JAMA 2005; 293: 2908–2917. [DOI] [PubMed] [Google Scholar]
  • 5. Fox KA, Poole‐Wilson P, Clayton TC, et al. 5‐year outcome of an interventional strategy in non‐ST‐elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366: 914–920. [DOI] [PubMed] [Google Scholar]
  • 6. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta‐analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48: 1319–1325. [DOI] [PubMed] [Google Scholar]
  • 7. Hoenig MR, Doust JA, Aroney CN, et al. Early invasive versus conservative strategies for unstable angina & non‐ST‐elevation myocardial infarction in the stent era. Cochrane Database Syst Rev 2006; 3: CD004815. [DOI] [PubMed] [Google Scholar]
  • 8. de Winter RJ, Windhausen F, Cornel JH, et al; Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353: 1095–1104. [DOI] [PubMed] [Google Scholar]
  • 9. Mehta SR, Granger CB, Boden WE, et al; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165–2175. [DOI] [PubMed] [Google Scholar]
  • 10. Montalescot G; on behalf of the ABOARD Investigators. A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non‐ST Elevation ACS. Presented at: American College of Cardiology 58th Annual Scientific Session, March 28–31, 2009; , Orlando, Florida.
  • 11. Pollack CV Jr, Braunwald E. 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non‐ST‐segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 2008; 51: 591–606. [DOI] [PubMed] [Google Scholar]
  • 12. Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–2216. [DOI] [PubMed] [Google Scholar]
  • 13. Stone GW, Bertrand ME, Moses JW, et al; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing Trial. JAMA 2007; 297: 591–602. [DOI] [PubMed] [Google Scholar]
  • 14. Stone GW, White HD, Ohman EM, et al; Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial Investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907–919. [DOI] [PubMed] [Google Scholar]
  • 15. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54. [DOI] [PubMed] [Google Scholar]
  • 16. Mahaffey KW, Cohen M, Garg J, et al; SYNERGY Trial Investigators. High‐risk patients with acute coronary syndromes treated with low‐molecular‐weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005; 294: 2594–2600. [DOI] [PubMed] [Google Scholar]
  • 17. Yusuf S, Mehta SR, Chrolavicius S, et al; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464–1476. [DOI] [PubMed] [Google Scholar]
  • 18. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403. [DOI] [PubMed] [Google Scholar]
  • 19. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–1375. [DOI] [PubMed] [Google Scholar]
  • 20. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–1111. [DOI] [PubMed] [Google Scholar]
  • 21. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable Angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: the PCI‐CURE study. Lancet 2001; 358: 527–533. [DOI] [PubMed] [Google Scholar]
  • 22.The CAPTURE Investigators. Randomised placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–1435. [PubMed] [Google Scholar]
  • 23.The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM‐PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497. [DOI] [PubMed] [Google Scholar]
  • 24.The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443. [DOI] [PubMed] [Google Scholar]
  • 25. Kastrati A, Mehilli J, Schühlen H, et al; Intracoronary Stenting and Antithrombotic Regimen—Rapid Early Action for Coronary Treatment (ISAR‐REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232–238. [DOI] [PubMed] [Google Scholar]
  • 26. Kastrati A, Mehilli J, Neumann F‐J, et al; Intracoronary Stenting and Antithrombotic Regimen—Rapid Early Action for Coronary Treatment (ISAR‐REACT) Study Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR‐REACT 2 randomized trial. JAMA 2006; 295: 1531–1538. [DOI] [PubMed] [Google Scholar]
  • 27. Ndrepepa G, Kastrati A, Mehilli J, et al. One‐year clinical outcomes with abciximab vs placebo in patients with non‐ST‐segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre‐treatment with clopidogrel: results of the ISAR‐REACT 2 randomized trial. Eur Heart J 2008; 29: 455–461. [DOI] [PubMed] [Google Scholar]
  • 28. Giugliano RP, White JA, Bode C, et al; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360: 2176–2190. [DOI] [PubMed] [Google Scholar]
  • 29. Bhatt DL, Roe MT, Peterson ED, et al; CRUSADE Investigators. Utilization of early invasive management strategies for high‐risk patients with non‐ST‐segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096–2104. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES